Crosstalk between purinergic receptor P2Y
CCL20
CXCR4
CXCR7
Cyclic AMP
EGFR
P2Y11
PDE4
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
received:
03
11
2023
accepted:
05
02
2024
revised:
22
01
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
epublish
Résumé
P2Y
Identifiants
pubmed: 38472446
doi: 10.1007/s00018-024-05158-7
pii: 10.1007/s00018-024-05158-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
132Informations de copyright
© 2024. The Author(s).
Références
Hughes CE, Nibbs RJB (2018) A guide to chemokines and their receptors. FEBS J 285:2944–2971. https://doi.org/10.1111/febs.14466
doi: 10.1111/febs.14466
pubmed: 29637711
pmcid: 6120486
Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y et al (2023) CXCL12-CXCR4/CXCR7 Axis in Cancer: from mechanisms to clinical applications. Int J Biol Sci 19:3341–3359. https://doi.org/10.7150/ijbs.82317
doi: 10.7150/ijbs.82317
pubmed: 37497001
pmcid: 10367567
Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N et al (2004) Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 5:943–952. https://doi.org/10.1038/ni1100
doi: 10.1038/ni1100
pubmed: 15300245
Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201:1307–1318. https://doi.org/10.1084/jem.20041385
doi: 10.1084/jem.20041385
pubmed: 15837815
pmcid: 2213145
Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al (2004) Rapid mobilization of CD34 + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and Non-hodgkin’s lymphoma. J Clin Oncol 22:1095–1102. https://doi.org/10.1200/JCO.2004.07.131
doi: 10.1200/JCO.2004.07.131
pubmed: 15020611
Niimi K, Kohara M, Sedoh E, Fukumoto M, Shibata S, Sawano T et al (2020) FOXO1 regulates developmental lymphangiogenesis by upregulating CXCR4 in the mouse-tail dermis. Development 147:dev181545. https://doi.org/10.1242/dev.181545
doi: 10.1242/dev.181545
pubmed: 31852686
Dominguez-Sola D, Kung J, Holmes AB, Wells VA, Mo T, Basso K et al (2015) The FOXO1 transcription factor instructs the Germinal Center Dark Zone Program. Immunity 43:1064–1074. https://doi.org/10.1016/j.immuni.2015.10.015
doi: 10.1016/j.immuni.2015.10.015
pubmed: 26620759
Perpina-Viciano C, Isbilir A, Zarca A, Caspar B, Kilpatrick LE, Hill SJ et al (2020) Kinetic analysis of the Early Signaling steps of the human chemokine receptor CXCR4. Mol Pharmacol 98:72–87. https://doi.org/10.1124/mol.119.118448
doi: 10.1124/mol.119.118448
pubmed: 32474443
pmcid: 7330677
Ward RJ, Pediani JD, Marsango S, Jolly R, Stoneman MR, Biener G et al (2021) Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t. J Biol Chem 296:100139. https://doi.org/10.1074/jbc.RA120.016612
doi: 10.1074/jbc.RA120.016612
pubmed: 33268380
Rosenberg EM Jr., Harrison RES, Tsou LK, Drucker N, Humphries B, Rajasekaran D et al (2019) Characterization, Dynamics, and mechanism of CXCR4 antagonists on a constitutively active mutant. Cell Chem Biol 26:662–73e7. https://doi.org/10.1016/j.chembiol.2019.01.012
doi: 10.1016/j.chembiol.2019.01.012
pubmed: 30827936
pmcid: 6736600
Pawig L, Klasen C, Weber C, Bernhagen J, Noels H (2015) Diversity and inter-connections in the CXCR4 chemokine Receptor/Ligand family: molecular perspectives. Front Immunol 6:429. https://doi.org/10.3389/fimmu.2015.00429
doi: 10.3389/fimmu.2015.00429
pubmed: 26347749
pmcid: 4543903
Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E et al (2005) RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280:33178–33189. https://doi.org/10.1074/jbc.M414316200
doi: 10.1074/jbc.M414316200
pubmed: 16030021
Wang C, Chen W, Shen J (2018) CXCR7 targeting and its Major Disease Relevance. Front Pharmacol 9:641. https://doi.org/10.3389/fphar.2018.00641
doi: 10.3389/fphar.2018.00641
pubmed: 29977203
pmcid: 6021539
Fan X, He L, Dai Q, He J, Chen X, Dai X et al (2020) Interleukin-1beta augments the angiogenesis of endothelial progenitor cells in an NF-kappaB/CXCR7-dependent manner. J Cell Mol Med 24:5605–5614. https://doi.org/10.1111/jcmm.15220
doi: 10.1111/jcmm.15220
pubmed: 32239650
pmcid: 7214148
Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP et al (2010) Beta-arrestin- but not G protein-mediated signaling by the decoy receptor CXCR7. Proc Natl Acad Sci U S A 107:628–632. https://doi.org/10.1073/pnas.0912852107
doi: 10.1073/pnas.0912852107
pubmed: 20018651
Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B (2009) CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113:6085–6093. https://doi.org/10.1182/blood-2008-12-196618
doi: 10.1182/blood-2008-12-196618
pubmed: 19380869
Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P (2011) CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem 286:32188–32197. https://doi.org/10.1074/jbc.M111.277038
doi: 10.1074/jbc.M111.277038
pubmed: 21730065
pmcid: 3173186
Uto-Konomi A, McKibben B, Wirtz J, Sato Y, Takano A, Nanki T et al (2013) CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4. Biochem Biophys Res Commun 431:772–776. https://doi.org/10.1016/j.bbrc.2013.01.032
doi: 10.1016/j.bbrc.2013.01.032
pubmed: 23333329
Duval V, Alayrac P, Silvestre JS, Levoye A (2022) Emerging roles of the atypical chemokine receptor 3 (ACKR3) in Cardiovascular diseases. Front Endocrinol (Lausanne) 13:906586. https://doi.org/10.3389/fendo.2022.906586
doi: 10.3389/fendo.2022.906586
pubmed: 35846294
Cao Z, Lis R, Ginsberg M, Chavez D, Shido K, Rabbany SY et al (2016) Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. Nat Med 22:154–162. https://doi.org/10.1038/nm.4035
doi: 10.1038/nm.4035
pubmed: 26779814
pmcid: 4872630
Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ et al (2010) The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 70:3299–3308. https://doi.org/10.1158/0008-5472.CAN-09-3642
doi: 10.1158/0008-5472.CAN-09-3642
pubmed: 20388803
Gritsina G, Yu J (2023) CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene 42. https://doi.org/10.1038/s41388-023-02597-7 . :785 – 92
Klaver D, Thurnher M (2021) Control of macrophage inflammation by P2Y purinergic receptors. Cells 10:1098. https://doi.org/10.3390/cells10051098
doi: 10.3390/cells10051098
pubmed: 34064383
pmcid: 8147772
Klaver D, Thurnher M (2023) P2Y(11)/IL-1 receptor crosstalk controls macrophage inflammation: a novel target for anti-inflammatory strategies? Purinergic Signal 19:501–511. https://doi.org/10.1007/s11302-023-09932-3
doi: 10.1007/s11302-023-09932-3
pubmed: 37016172
pmcid: 10073626
Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kugelgen I, Li B et al (2020) Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol 177:2413–2433. https://doi.org/10.1111/bph.15005
doi: 10.1111/bph.15005
pubmed: 32037507
pmcid: 7205808
Layhadi JA, Turner J, Crossman D, Fountain SJ (2018) ATP Evokes Ca(2+) Responses and CXCL5 Secretion via P2X4 Receptor Activation in Human Monocyte-Derived Macrophages. J Immunol 200:1159–1168. https://doi.org/10.4049/jimmunol.1700965
doi: 10.4049/jimmunol.1700965
pubmed: 29255078
Gruenbacher G, Gander H, Rahm A, Dobler G, Drasche A, Troppmair J et al (2019) The human G protein-coupled ATP receptor P2Y11 is Associated with IL-10 driven macrophage differentiation. Front Immunol 10:1870. https://doi.org/10.3389/fimmu.2019.01870
doi: 10.3389/fimmu.2019.01870
pubmed: 31447857
pmcid: 6695557
Communi D, Govaerts C, Parmentier M, Boeynaems JM (1997) Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 272:31969–31973. https://doi.org/10.1074/jbc.272.51.31969
doi: 10.1074/jbc.272.51.31969
pubmed: 9405388
Shirakawa F, Yamashita U, Chedid M, Mizel SB (1988) Cyclic AMP–an intracellular second messenger for interleukin 1. Proc Natl Acad Sci U S A 85:8201–8205. https://doi.org/10.1073/pnas.85.21.8201
doi: 10.1073/pnas.85.21.8201
pubmed: 2847154
pmcid: 282395
Gruenbacher G, Gander H, Dobler G, Rahm A, Klaver D, Thurnher M (2021) The human G protein-coupled ATP receptor P2Y11 is a target for anti-inflammatory strategies. Br J Pharmacol 178:1541–1555. https://doi.org/10.1111/bph.15379
doi: 10.1111/bph.15379
pubmed: 33463722
Klaver D, Gander H, Dobler G, Rahm A, Thurnher M (2022) The P2Y(11) receptor of human M2 macrophages activates canonical and IL-1 receptor signaling to translate the extracellular danger signal ATP into anti-inflammatory and pro-angiogenic responses. Cell Mol Life Sci 79:519. https://doi.org/10.1007/s00018-022-04548-z
doi: 10.1007/s00018-022-04548-z
pubmed: 36107259
pmcid: 9476423
Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872–877. https://doi.org/10.1126/science.272.5263.872
doi: 10.1126/science.272.5263.872
pubmed: 8629022
Kelly JJ, Barnes PJ, Giembycz MA (1996) Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. Biochem J 318(Pt 2):425–436. https://doi.org/10.1042/bj3180425
doi: 10.1042/bj3180425
pubmed: 8809029
pmcid: 1217639
Matti C, D’Uonnolo G, Artinger M, Melgrati S, Salnikov A, Thelen S et al (2020) CCL20 is a novel ligand for the scavenging atypical chemokine receptor 4. J Leukoc Biol 107:1137–1154. https://doi.org/10.1002/JLB.2MA0420-295RRR
doi: 10.1002/JLB.2MA0420-295RRR
pubmed: 32533638
Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77:1627–1652
doi: 10.1182/blood.V77.8.1627.1627
pubmed: 1826616
Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N et al (2010) NF546 [4,4’-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-car bonylimino))-bis(1,3-xylene-alpha,alpha’-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther 332:238–247. https://doi.org/10.1124/jpet.109.157750
doi: 10.1124/jpet.109.157750
pubmed: 19815812
Daub H, Weiss FU, Wallasch C, Ullrich A (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379:557–560. https://doi.org/10.1038/379557a0
doi: 10.1038/379557a0
pubmed: 8596637
Salazar N, Munoz D, Kallifatidis G, Singh RK, Jorda M, Lokeshwar BL (2014) The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation. Mol Cancer 13:198. https://doi.org/10.1186/1476-4598-13-198
doi: 10.1186/1476-4598-13-198
pubmed: 25168820
pmcid: 4167278
Singh RK, Lokeshwar BL (2011) The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 71:3268–3277. https://doi.org/10.1158/0008-5472.CAN-10-2769
doi: 10.1158/0008-5472.CAN-10-2769
pubmed: 21398406
pmcid: 3085571
Hippe A, Braun SA, Olah P, Gerber PA, Schorr A, Seeliger S et al (2020) EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer 123:942–954. https://doi.org/10.1038/s41416-020-0943-2
doi: 10.1038/s41416-020-0943-2
pubmed: 32601464
pmcid: 7493992
Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F et al (2022) EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv 8:eabn7983. https://doi.org/10.1126/sciadv.abn7983
doi: 10.1126/sciadv.abn7983
pubmed: 36525493
pmcid: 9757751
Furue K, Ito T, Tanaka Y, Hashimoto-Hachiya A, Takemura M, Murata M et al (2020) The EGFR-ERK/JNK-CCL20 pathway in scratched keratinocytes may underpin koebnerization in Psoriasis patients. Int J Mol Sci 21:434. https://doi.org/10.3390/ijms21020434
doi: 10.3390/ijms21020434
pubmed: 31936670
pmcid: 7013594
Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310. https://doi.org/10.1038/sj.onc.1210422
doi: 10.1038/sj.onc.1210422
pubmed: 17496923
Ohtsu H, Dempsey PJ, Eguchi S (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291:C1–10. https://doi.org/10.1152/ajpcell.00620.2005
doi: 10.1152/ajpcell.00620.2005
pubmed: 16769815
Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM (2008) Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 314:2907–2918. https://doi.org/10.1016/j.yexcr.2008.07.013
doi: 10.1016/j.yexcr.2008.07.013
pubmed: 18687326
Zhao G, Liu L, Peek RM Jr., Hao X, Polk DB, Li H et al (2016) Activation of Epidermal Growth Factor Receptor in Macrophages mediates feedback inhibition of M2 polarization and gastrointestinal tumor cell growth. J Biol Chem 291:20462–20472. https://doi.org/10.1074/jbc.M116.750182
doi: 10.1074/jbc.M116.750182
pubmed: 27507810
pmcid: 5034042
De Clercq E (2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2:581–587. https://doi.org/10.1038/nrd1134
doi: 10.1038/nrd1134
pubmed: 12815382
McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E et al (2019) Plerixafor for the treatment of WHIM Syndrome. N Engl J Med 380:163–170. https://doi.org/10.1056/NEJMoa1808575
doi: 10.1056/NEJMoa1808575
pubmed: 30625055
pmcid: 6425947
Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75:1240–1247. https://doi.org/10.1124/mol.108.053389
doi: 10.1124/mol.108.053389
pubmed: 19255243
Gravel S, Malouf C, Boulais PE, Berchiche YA, Oishi S, Fujii N et al (2010) The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem 285:37939–37943. https://doi.org/10.1074/jbc.C110.147470
doi: 10.1074/jbc.C110.147470
pubmed: 20956518
pmcid: 2992227
Wang K, Sun S, Zhang G, Lu Z, Chen H, Fan X et al (2022) CXCR7 agonist TC14012 improves angiogenic function of endothelial progenitor cells via activating Akt/eNOS pathway and promotes ischemic angiogenesis in Diabetic Limb Ischemia. Cardiovasc Drugs Ther 37:849–863. https://doi.org/10.1007/s10557-022-07337-9
doi: 10.1007/s10557-022-07337-9
pubmed: 35471717
pmcid: 10926281
Wong RS, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP (2008) Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74:1485–1495. https://doi.org/10.1124/mol.108.049775
doi: 10.1124/mol.108.049775
pubmed: 18768385
Berg C, Daugvilaite V, Steen A, Jorgensen AS, Vabeno J, Rosenkilde MM (2018) Inhibition of HIV Fusion by Small Molecule agonists through Efficacy-Engineering of CXCR4. ACS Chem Biol 13:881–886. https://doi.org/10.1021/acschembio.8b00061
doi: 10.1021/acschembio.8b00061
pubmed: 29461034
Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD (2010) Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 29:4599–4610. https://doi.org/10.1038/onc.2010.212
doi: 10.1038/onc.2010.212
pubmed: 20531309
pmcid: 3164491
Wijtmans M, Maussang D, Sirci F, Scholten DJ, Canals M, Mujic-Delic A et al (2012) Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem 51:184–192. https://doi.org/10.1016/j.ejmech.2012.02.041
doi: 10.1016/j.ejmech.2012.02.041
pubmed: 22424612
Sarma P, Carino CMC, Seetharama D, Pandey S, Dwivedi-Agnihotri H, Rui X et al (2023) Molecular insights into intrinsic transducer-coupling bias in the CXCR4-CXCR7 system. Nat Commun 14:4808. https://doi.org/10.1038/s41467-023-40482-9
doi: 10.1038/s41467-023-40482-9
pubmed: 37558722
pmcid: 10412580
Nguyen HT, Reyes-Alcaraz A, Yong HJ, Nguyen LP, Park HK, Inoue A et al (2020) CXCR7: a beta-arrestin-biased receptor that potentiates cell migration and recruits beta-arrestin2 exclusively through gbetagamma subunits and GRK2. Cell Biosci 10:134. https://doi.org/10.1186/s13578-020-00497-x
doi: 10.1186/s13578-020-00497-x
pubmed: 33292475
pmcid: 7686738
Ledderose C, Bromberger S, Slubowski CJ, Sueyoshi K, Aytan D, Shen Y et al (2020) The purinergic receptor P2Y11 choreographs the polarization, mitochondrial metabolism, and migration of T lymphocytes. Sci Signal 13:eaba3300. https://doi.org/10.1126/scisignal.aba3300
doi: 10.1126/scisignal.aba3300
pubmed: 32994212
pmcid: 8826773
Marteau F, Gonzalez NS, Communi D, Goldman M, Boeynaems JM, Communi D (2005) Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. Blood 106:3860–3866. https://doi.org/10.1182/blood-2005-05-1843
doi: 10.1182/blood-2005-05-1843
pubmed: 16118322
Lee AY, Eri R, Lyons AB, Grimm MC, Korner H (2013) CC Chemokine Ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or Axis of Evil? Front Immunol 4:194. https://doi.org/10.3389/fimmu.2013.00194
doi: 10.3389/fimmu.2013.00194
pubmed: 23874340
pmcid: 3711275
Meitei HT, Jadhav N, Lal G (2021) CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmun Rev 20:102846. https://doi.org/10.1016/j.autrev.2021.102846
doi: 10.1016/j.autrev.2021.102846
pubmed: 33971346
Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F et al (2020) COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol 38:970–979. https://doi.org/10.1038/s41587-020-0602-4
doi: 10.1038/s41587-020-0602-4
pubmed: 32591762
Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F et al (2020) Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell 183:982 – 95 e14. https://doi.org/10.1016/j.cell.2020.09.034
Kadomoto S, Izumi K, Mizokami A (2020) The CCL20-CCR6 Axis in Cancer Progression. Int J Mol Sci 21:5186. https://doi.org/10.3390/ijms21155186
doi: 10.3390/ijms21155186
pubmed: 32707869
pmcid: 7432448
Sanchez-Alcaniz JA, Haege S, Mueller W, Pla R, Mackay F, Schulz S et al (2011) Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 69:77–90. https://doi.org/10.1016/j.neuron.2010.12.006
doi: 10.1016/j.neuron.2010.12.006
pubmed: 21220100
Lowe JM, Menendez D, Bushel PR, Shatz M, Kirk EL, Troester MA et al (2014) p53 and NF-kappaB coregulate proinflammatory gene responses in human macrophages. Cancer Res 74:2182–2192. https://doi.org/10.1158/0008-5472.CAN-13-1070
doi: 10.1158/0008-5472.CAN-13-1070
pubmed: 24737129
pmcid: 3994464
Horn S, Hughes MA, Schilling R, Sticht C, Tenev T, Ploesser M et al (2017) Caspase-10 negatively regulates caspase-8-Mediated cell death, switching the response to CD95L in Favor of NF-kappaB activation and cell survival. Cell Rep 19:785–797. https://doi.org/10.1016/j.celrep.2017.04.010
doi: 10.1016/j.celrep.2017.04.010
pubmed: 28445729
pmcid: 5413585
Chu X, Jin Q, Chen H, Wood GC, Petrick A, Strodel W et al (2018) CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading. J Transl Med 16:108. https://doi.org/10.1186/s12967-018-1490-y
doi: 10.1186/s12967-018-1490-y
pubmed: 29690903
pmcid: 5937820
Schroder K, Irvine KM, Taylor MS, Bokil NJ, Le Cao KA, Masterman KA et al (2012) Conservation and divergence in toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci U S A 109:E944–E953. https://doi.org/10.1073/pnas.1110156109
doi: 10.1073/pnas.1110156109
pubmed: 22451944
pmcid: 3341041
Neill O LA (2000) The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2000(re1). https://doi.org/10.1126/stke.442000re1
Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G (2000) Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 67:97–103
doi: 10.1002/jlb.67.1.97
pubmed: 10648003
Xu ZJ, Gu Y, Wang CZ, Jin Y, Wen XM, Ma JC et al (2020) The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia. Oncoimmunology 9:1683347. https://doi.org/10.1080/2162402X.2019.1683347
doi: 10.1080/2162402X.2019.1683347
pubmed: 32002295